New insider activity at Medpace Holdings ( (MEDP) ) has taken place on March 19, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Medpace Holdings has seen notable insider activity as President Jesse J. Geiger sold 31,707 shares of the company’s stock in a recent transaction. The total value of the sale amounted to $14,436,197, highlighting a significant move by a top executive within the organization.
Recent Updates on MEDP stock
Medpace shares reacted to fresh analyst commentary in the last day, with Barclays upgrading the stock as it now sees the valuation as more reasonable while noting ongoing contract wins and a lower‑than‑feared impact from faster‑burning projects rolling off. Separately, RBC Capital started coverage, arguing Medpace is among the most efficient CROs and is strongly leveraged to improving biopharma clinical trial activity, which it sees driving segment‑leading growth and margins versus larger peers.
Spark’s Take on MEDP Stock
According to Spark, TipRanks’ AI Analyst, MEDP is a Outperform.
The score is driven primarily by strong financial performance (steady multi-year growth, high profitability, modest leverage, and excellent free cash flow) and supportive 2026 guidance/backlog visibility from the earnings call. These positives are tempered by weak technical momentum (below key moving averages with negative MACD) and a premium valuation (P/E ~37) that raises execution risk.
To see Spark’s full report on MEDP stock, click here.
More about Medpace Holdings
YTD Price Performance: -19.02%
Average Trading Volume: 325,852
Technical Sentiment Signal: Buy
Current Market Cap: $12.91B